Multiple System AtrophySymptoms, Doctors, Treatments, Advances & More
Learn About Multiple System Atrophy
Multiple system atrophy- parkinsonian type (MSA-P) is a rare condition that causes symptoms similar to Parkinson disease. However, people with MSA-P have more widespread damage to the part of the nervous system that regulates important functions such as heart rate, blood pressure, and sweating.
The other subtype of MSA is MSA-cerebellar. It mainly affects the cerebellum, an area deep in the brain, just above the spinal cord.
Shy-Drager syndrome; Neurologic orthostatic hypotension; Shy-McGee-Drager syndrome; Parkinson plus syndrome; MSA-P; MSA-C
The cause of MSA-P is unknown. The affected areas of the brain overlap with areas affected by Parkinson disease, with similar symptoms. For this reason, this subtype of MSA is called parkinsonian.
MSA-P is most often diagnosed in men older than 60.
MSA damages the nervous system. The disease tends to progress rapidly. About one half of people with MSA-P have lost most of their motor skills within 5 years of onset of the disease.
Symptoms may include:
- Passing out (syncope) due to drops in blood pressure
- Tremors
- Movement difficulties, such as slowness, loss of balance, shuffling when walking
- Frequent falls
- Muscle aches and pains (myalgia), and stiffness
- Face changes, such as a masklike appearance to the face and staring
- Difficulty chewing or swallowing (occasionally), not able to close the mouth
- Disrupted sleep patterns (often during rapid eye movement [REM] sleep late at night)
- Dizziness or fainting when standing up or after standing still
- Erection problems
- Loss of control over bowels or bladder
- Problems with activities that requires small movements (loss of fine motor skills), such as writing that is small and hard to read
- Loss of sweating in any part of the body
- Decline in mental function
- Nausea and problems with digestion
- Posture problems, such as unstable, stooped, or slumped over
- Vision changes, decreased or blurred vision
- Voice and speech changes
Other symptoms that may occur with this disease:
- Confusion
- Dementia
- Depression
- Sleep-related breathing difficulties, including sleep apnea or a blockage in the air passage that leads to a harsh vibrating sound
- Restless legs
There is no cure for MSA-P. There is no known way to prevent the disease from getting worse. The goal of treatment is to control symptoms.
Dopaminergic medicines, such as levodopa and carbidopa, may be used to reduce early or mild tremors.
But, for many people with MSA-P, these medicines do not work well.
Medicines may be used to treat low blood pressure.
A pacemaker that is programmed to stimulate the heart to beat at a rapid rate (faster than 100 beats per minute) may increase blood pressure for some people.
Constipation can be treated with a high-fiber diet and laxatives. Medicines are available to treat erection problems.
BIDMC Department Of Neurology
Christopher Gibbons is a Neurologist practicing medicine in Boston, Massachusetts. Dr. Gibbons is rated as an Elite provider by MediFind in the treatment of Multiple System Atrophy. He is also highly rated in 13 other conditions, according to our data. His clinical expertise encompasses Familial Dysautonomia, Orthostatic Hypotension, Multiple System Atrophy, Osteotomy, and Knee Replacement. Dr. Gibbons is board certified in American Board Of Psychiatry And Neurology.
BIDMC Department Of Neurology
Roy Freeman is a Neurologist practicing medicine in Boston, Massachusetts. Dr. Freeman is rated as an Elite provider by MediFind in the treatment of Multiple System Atrophy. He is also highly rated in 19 other conditions, according to our data. His clinical expertise encompasses Orthostatic Hypotension, Familial Dysautonomia, Low Blood Pressure, and Multiple System Atrophy. Dr. Freeman is board certified in American Board Of Psychiatry And Neurology.
Vanderbilt Heart Transplant
Italo Biaggioni is an Internal Medicine provider practicing medicine in Nashville, Tennessee. Dr. Biaggioni is rated as an Elite provider by MediFind in the treatment of Multiple System Atrophy. He is also highly rated in 11 other conditions, according to our data. His clinical expertise encompasses Familial Dysautonomia, Orthostatic Hypotension, Low Blood Pressure, and Postural Orthostatic Tachycardia Syndrome (POTS).
More information and support for people with MSA-P and their families can be found at:
- National Organization for Rare Disorders -- rarediseases.org/rare-diseases/multiple-system-atrophy
- The MSA Coalition -- missionmsa.org
The outcome for MSA is poor. Loss of mental and physical functions slowly get worse. Early death is likely. People typically live 7 to 9 years after diagnosis.
Contact your provider if you develop symptoms of this disorder.
Contact your provider if you have been diagnosed with MSA and your symptoms return or get worse. Also contact your provider if new symptoms appear, including possible side effects of medicines, such as:
- Changes in alertness/behavior/mood
- Delusional behavior
- Dizziness
- Hallucinations
- Involuntary movements
- Loss of mental functioning
- Nausea or vomiting
- Severe confusion or disorientation
If you have a family member with MSA and their condition declines to the point that you are unable to care for the person at home, seek advice from your family member's provider.
Summary: This clinical trial is designed to evaluate the safety, tolerability and preliminary efficacy of a single injection of NouvNeu001 (Human Dopaminergic Progenitor Cells Injection) in patients with Multiple System Atrophy.
Summary: The primary objective of the trial is to describe the long-term safety and tolerability of TEV-56286 administered orally for the treatment of adult participants with Multiple System Atrophy (MSA). A secondary objective of the trial is to further describe the safety and tolerability of TEV-56286. The planned total duration of the trial is approximately 100 weeks.
Published Date: October 23, 2024
Published By: Joseph V. Campellone, MD, Department of Neurology, Cooper Medical School at Rowan University, Camden, NJ. Review provided by VeriMed Healthcare Network. Also reviewed by David C. Dugdale, MD, Medical Director, Brenda Conaway, Editorial Director, and the A.D.A.M. Editorial team.
Jankovic J. Parkinson disease and other movement disorders. In: Jankovic J, Mazziotta JC, Pomeroy SL, Newman NJ, eds. Bradley and Daroff's Neurology in Clinical Practice. 8th ed. Philadelphia, PA: Elsevier; 2022:chap 96.
National Institutes of Health website. National Institute of Neurological Disorders and Stroke. Multiple system atrophy. www.ninds.nih.gov/health-information/disorders/multiple-system-atrophy. Updated July 19, 2024. Accessed November 4, 2024.
Romero-Ortuno R, Wilson KJ, Hampton JL. Disorders of the autonomic nervous system. In: Fillit HM, Rockwood K, Young J, eds. Brocklehurst's Textbook of Geriatric Medicine and Gerontology. 8th ed. Philadelphia, PA: Elsevier; 2017:chap 63.